CAR-T Therapy Targeting Solid Tumor

Abstract

The chimeric antigen receptor (CAR) is a receptor that introduces the specificity of the immune cell to the tumor. CAR was first developed in the mid-1980s. CARs have evolved from first-generation CARs to fourth-generation CARs. Generally, CAR-T is made by separating and activating T cells from the patient’s blood and then using virus vectors to form CARs. CAR-T has successful clinical results in the treatment of hematologic malignancies, and there are U.S. FDA-approved drugs. Although solid tumor research is being actively conducted, the results of clinical trials on solid tumor are still not as expected. Therefore, it is necessary to study CAR-T therapy, especially efficacy and stability of CAR-T cells against solid tumors.